These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37285140)

  • 1. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
    Kuemmel S; Heil J; Bruzas S; Breit E; Schindowski D; Harrach H; Chiari O; Hellerhoff K; Bensmann E; Hanf V; Graßhoff ST; Deuschle P; Belke K; Polata S; Paepke S; Warm M; Meiler J; Schindlbeck C; Ruhwedel W; Beckmann U; Groh U; Dall P; Blohmer JU; Traut A; Reinisch M
    JAMA Surg; 2023 Aug; 158(8):807-815. PubMed ID: 37285140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.
    Montagna G; Mrdutt MM; Sun SX; Hlavin C; Diego EJ; Wong SM; Barrio AV; van den Bruele AB; Cabioglu N; Sevilimedu V; Rosenberger LH; Hwang ES; Ingham A; Papassotiropoulos B; Nguyen-Sträuli BD; Kurzeder C; Aybar DD; Vorburger D; Matlac DM; Ostapenko E; Riedel F; Fitzal F; Meani F; Fick F; Sagasser J; Heil J; Karanlik H; Dedes KJ; Romics L; Banys-Paluchowski M; Muslumanoglu M; Perez MDRC; Díaz MC; Heidinger M; Fehr MK; Reinisch M; Tukenmez M; Maggi N; Rocco N; Ditsch N; Gentilini OD; Paulinelli RR; Zarhi SS; Kuemmel S; Bruzas S; di Lascio S; Parissenti TK; Hoskin TL; Güth U; Ovalle V; Tausch C; Kuerer HM; Caudle AS; Boileau JF; Boughey JC; Kühn T; Morrow M; Weber WP
    JAMA Oncol; 2024 Jun; 10(6):793-798. PubMed ID: 38662396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study.
    Wu SY; Li JW; Wang YJ; Jin KR; Yang BL; Li JJ; Yu XL; Mo M; Hu N; Shao ZM; Liu GY
    Int J Surg; 2023 Jul; 109(7):1863-1870. PubMed ID: 37132193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementation of the Targeted Axillary Dissection Procedure in Clinically Node-Positive Breast Cancer: A Retrospective Analysis.
    Nijveldt JJ; Rajan KK; Boersma K; Noorda EM; van der Starre-Gaal J; Kate MV'V; Roeloffzen EMA; Vendel BN; Beek MA; Francken AB
    Ann Surg Oncol; 2024 Jul; 31(7):4477-4486. PubMed ID: 38523225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry.
    Loveland-Jones C; Gaughan J; Caudle A; Murphy B; Samiian L; Byrum S; Brill K; Germaine P; Zhang X; Yoon-Flannery K; Carter T; Lopez A; Gruner R; Fantazzio M; Kuerer H
    Eur J Surg Oncol; 2024 Apr; 50(4):108245. PubMed ID: 38484493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment.
    Siso C; Esgueva A; Rivero J; Morales C; Miranda I; Peg V; Gil-Moreno A; Espinosa-Bravo M; Rubio IT
    Eur J Surg Oncol; 2023 Oct; 49(10):106938. PubMed ID: 37244843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. False-negative rate in the extended prospective TATTOO trial evaluating targeted axillary dissection by carbon tattooing in clinically node-positive breast cancer patients receiving neoadjuvant systemic therapy.
    de Boniface J; Frisell J; Kühn T; Wiklander-Bråkenhielm I; Dembrower K; Nyman P; Zouzos A; Gerber B; Reimer T; Hartmann S
    Breast Cancer Res Treat; 2022 Jun; 193(3):589-595. PubMed ID: 35451733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncologic Outcomes for Different Axillary Staging Techniques in Patients with Nodal-Positive Breast Cancer Undergoing Neoadjuvant Systematic Treatment: A Cancer Registry Study.
    Pfob A; Kokh DB; Surovtsova I; Riedel F; Morakis P; Heil J
    Ann Surg Oncol; 2024 Jul; 31(7):4381-4392. PubMed ID: 38710911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy.
    Cabıoğlu N; Karanlık H; Yılmaz R; Emiroğlu S; Tükenmez M; Bademler S; Şimşek DH; Kantarcı TR; Yirgin İK; Bayram A; Dursun M
    World J Surg Oncol; 2024 Jul; 22(1):178. PubMed ID: 38971793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
    Simons JM; van Nijnatten TJA; van der Pol CC; van Diest PJ; Jager A; van Klaveren D; Kam BLR; Lobbes MBI; de Boer M; Verhoef C; Sars PRA; Heijmans HJ; van Haaren ERM; Vles WJ; Contant CME; Menke-Pluijmers MBE; Smit LHM; Kelder W; Boskamp M; Koppert LB; Luiten EJT; Smidt ML
    JAMA Surg; 2022 Nov; 157(11):991-999. PubMed ID: 36069889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
    Kuemmel S; Heil J; Rueland A; Seiberling C; Harrach H; Schindowski D; Lubitz J; Hellerhoff K; Ankel C; Graßhoff ST; Deuschle P; Hanf V; Belke K; Dall P; Dorn J; Kaltenecker G; Kuehn T; Beckmann U; Potenberg J; Blohmer JU; Kostara A; Breit E; Holtschmidt J; Traut E; Reinisch M
    Ann Surg; 2022 Nov; 276(5):e553-e562. PubMed ID: 33156057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does ultrasound evaluation of the axilla increase the rate of axillary lymph node dissection in early stage clinically node negative breast cancer patients?
    Vasigh M; Meshkati Yazd SM; Karoobi M; Hajebi R; Yazdankhah Kenari A
    BMC Surg; 2022 Mar; 22(1):80. PubMed ID: 35241059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
    van Loevezijn AA; van der Noordaa MEM; Stokkel MPM; van Werkhoven ED; Groen EJ; Loo CE; Elkhuizen PHM; Sonke GS; Russell NS; van Duijnhoven FH; Vrancken Peeters MTFD
    Breast Cancer Res Treat; 2022 May; 193(1):37-48. PubMed ID: 35239072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual Axillary Metastases in Node-Positive Breast Cancer Patients After Neoadjuvant Treatment: A Register-Based Study.
    Munck F; Jensen MB; Vejborg I; Gerlach MK; Maraldo MV; Kroman NT; Tvedskov THF
    Ann Surg Oncol; 2024 Aug; 31(8):5157-5167. PubMed ID: 38704502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
    Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
    Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Evaluation of Radar-Localized Reflector-Directed Targeted Axillary Dissection in Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy.
    Gallagher KK; Iles K; Kuzmiak C; Louie R; McGuire KP; Ollila DW
    J Am Coll Surg; 2022 Apr; 234(4):538-545. PubMed ID: 35290273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
    Pinto CS; Peleteiro B; Pinto CA; Osório F; Costa S; Magalhães A; Mora H; Amaral J; Gonçalves D; Fougo JL
    Breast Cancer; 2022 Jul; 29(4):709-719. PubMed ID: 35304711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
    Caudle AS; Yang WT; Krishnamurthy S; Mittendorf EA; Black DM; Gilcrease MZ; Bedrosian I; Hobbs BP; DeSnyder SM; Hwang RF; Adrada BE; Shaitelman SF; Chavez-MacGregor M; Smith BD; Candelaria RP; Babiera GV; Dogan BE; Santiago L; Hunt KK; Kuerer HM
    J Clin Oncol; 2016 Apr; 34(10):1072-8. PubMed ID: 26811528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
    Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
    Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.